AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05736874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study NCT06525428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab
Description: First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT
Study NCT05826912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Capsule, 80 mg/day, with no loading dose, for 28 days
Study NCT05826912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline Hydrochloride
Description: Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
Study NCT05826912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
Study NCT05826912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, 2x/day for 28 days
Study NCT05732116 — intervention group
Intervention type: OTHER
Intervention: PTSD
Description: Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
Study NCT05625360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Mindful Movement and Breathing
Description: The self-directed intervention includes an approximately 20-minute eMMB will teach synergistic components: (a) Mindful Meditation - 2 minutes of observing the current state of the body, emotions, thoughts, energy, and breath. Mindful attention may facilitate safe physical movements; (b) Mindful Movement - 10 minutes of gentle movements coordinated with and intended to enhance the breath; (c) Breathing and Relaxation - 3 minutes of placing the hands above the navel (rather than on the belly to avoid discomfort) and noticing them rise and fall with a focus on slightly extending the exhale, which will prepare participants for meditation); (d) Meditation - 5 minutes of observing the natural breath without reacting to it.
Study NCT05625360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life Impacts Reflection
Description: This self-directed intervention will focus on active listening, reflection of statements, and avoiding negative judgments. Participants will write brief diary entries daily for four weeks postoperatively and as they choose thereafter. Participants will be given the option of completing diaries on the tablet computer or paper. The instructions for daily diary entries will be, What were some of the events or circumstances that affected you in the past day? Think back over the past day and write down on the lines below up to five events that had an impact on you. A study team member will call participants to encourage diary completion two days (Postop Day 3) and two weeks after the synchronous session.
Study NCT05625360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS Questionnaires
Description: Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
Study NCT05625360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS Questionnaires
Description: Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
Study NCT05213975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio taping
Study NCT06343831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6)
Description: The study participant will be requested to stand upright with hands comfortably behind their back and turn 45 degrees and 90 degrees in either direction for standard anteroposterior (AP), oblique and lateral photos. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers. The photographs will be acquired using a commercially available camera or study iPad device.
Study NCT06343831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-Dimensional (3-D) Photographs (Visit 1- 6)
Description: 3-Dimensional surface scans of the participant's torso will be acquired using a commercially available handheld camera scanning device that offers texture, geometry, and color acquisition from any complex surface using white light technology, which is safe for exposure to skin and eyes. Prior to imaging, a pattern of lines and dots will be marked on the patient's breasts using a washable marker. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member moves around their torso with the handheld scanner. The exam room table will then be reclined to a lay-flat position such that the patient is laying supine, and breast imaging will be repeated. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers.
Study NCT06343831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6)
Description: The images will be acquired using a commercially available handheld ultrasound scanning device. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member obtains images of the specific area of the breast of chest wall to be grafted (V1) and that which was grafted (V4-6). Images usually take 5-10 minutes to acquire depending on the number of areas grafted.
Study NCT06343831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6)
Description: An MRI of the breast will be obtained around visit 1 and visits 4-6 timepoints. The images will be acquired in collaboration with the Breast Imaging Core and the Magnetic Resonance Research Imaging Center. Dr. Abe (co-investigator, radiology) will review the images to assess volume of the overall breast, the specific areas of the breasts that were grafted.
Study NCT06343831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6)
Description: The BREAST-QTM measures three satisfaction domains and three quality of life (QoL) domains.6 For BREAST-QTM, each domain has a score range from 0 - 100. A difference in score, either positive or negative, of 10 points is considered clinically important; a difference of 20 points is considered clinically very important. This survey will be administered to participants via iPad during visit 1 and visits 4-6 and takes approximately 10-20 minutes to complete.
Study NCT06077656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25 Formulation A
Description: 25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant
Study NCT06077656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25 Formulation B
Description: 25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant
Study NCT06077656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25 Formulation C
Description: 25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant
Study NCT06077656 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 20
Description: 20 valent pneumococcal conjugate vaccine
Study NCT05782868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing in response to vignette
Description: Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
Study NCT05782868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive writing about events of the day
Description: Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
Study NCT05782868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter of Gratitude
Description: Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
Study NCT05295849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Habits Together Online Weight Loss 6-Week Usability Trial
Description: The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
Study NCT06195709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Endocrine therapy
Description: Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
Study NCT06195709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
Study NCT06195709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Endocrine therapy combined with the local treatment of FES-negative lesions
Description: Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
Study NCT06195709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
Study NCT05397327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D virtual planning software
Description: 3D virtual planning software developed by Sectra AB (Linköping, Sweden)
Study NCT03101917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Microtable® Stereotactic System
Description: x
Study NCT04803383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Tele-yoga training 3 days a week for 8 weeks
Study NCT05738174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-dose accelerated intermittent theta burst stimulation
Description: 1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
Study NCT05738174 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high-dose accelerated intermittent theta burst stimulation
Description: 1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
Study NCT05747443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Reminders
Description: Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
Study NCT05747443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: The Patient Voices Video is an educational video about lung cancer screening.
Study NCT05473026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Intervention
Description: Gratitude journaling and goal setting for exercise readiness over eight weeks.
Study NCT05019690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W
Study NCT05019690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
Study NCT05206734 — intervention group
Intervention type: OTHER
Intervention: Exposure of mental health condition
Description: Primary:~Composite of all chronic psychological conditions (depression, anxiety, eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorder, acute stress disorder, and post-traumatic stress disorder).~Major recurrent depression or treated depressive episode. Non-phobia related anxiety episode or disorder.~Secondary:~Self-harm, suicide attempt or suicide related codes, other chronic psychiatric conditions (eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorders, acute stress disorder, schizophrenia, bipolar disorder and post-traumatic stress disorder. Problems with sleep.
Study NCT06186323 — intervention group
Intervention type: BEHAVIORAL
Intervention: Affordances in the Home Environment for Motor Development-Infant Scale
Description: Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
Study NCT06186323 — intervention group
Intervention type: BEHAVIORAL
Intervention: Peabody Developmental Motor Scales-2
Description: Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills
Study NCT06186323 — intervention group
Intervention type: BEHAVIORAL
Intervention: Test Of Sensory Functions In Infants (TSFI)
Description: his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
Study NCT04861597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet based cognitive behavioral therapy
Description: Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
Study NCT04861597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital mood tracking
Description: Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
Study NCT06092749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transgrade technique (TG)
Description: Transgrade (TG) Epidural Steroid Injection technique
Study NCT06092749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interlaminar technique (IL)
Description: Interlaminar (IL) Epidural Steroid Injection technique
Study NCT05517135 — intervention group
Intervention type: OTHER
Intervention: Arm 1
Description: Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC). For AC, physicians can choose between cisplatin-5FU d1-4, q4w for 3 cycles, or capecitabine 650 mg/m2 bid for 12 months or 1000 mg/m2 bid oral, d1-21, q3w for 6 months
Study NCT05517135 — intervention group
Intervention type: OTHER
Intervention: Arm 2
Description: IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT +/- metronomic capecitabine (650 mg/m2 bid oral for 12 months)
Study NCT05517135 — intervention group
Intervention type: OTHER
Intervention: Arm 3
Description: IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), followed by either of the following:~1. RIBBON-LA-01 (NCT06093061)~2. CCRT + metronomic capecitabine (650 mg/m2 bid oral for 12 months)
Study NCT05517135 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine
Study NCT05517135 — intervention group
Intervention type: OTHER
Intervention: Group 2
Description: Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
Study NCT05753046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early TAP Block
Description: For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
Study NCT05753046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Late TAP Block
Description: For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
Study NCT06533969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation
Description: This will be a one time surgery lasting no more than 2 hours where ESCS electrodes will be connected to an external stimulator approved for human research. Stimulation intensity and parameters will be configured before each session for optimal upper extremity motor function.~The ESCS approach will include surgical implantation of temporarily placed leads in the cervical epidural space and connection cables tunneled percutaneously through the skin for \<30 days
Study NCT06533969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocorticographic
Description: Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
Study NCT06533969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalographic
Description: Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
Study NCT05899153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomotum Spark: Robotic ankle resistance
Description: Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.